2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P10005
    D-Val-Gly-Arg-pNA 98%
    D-Val-Gly-Arg-pNA is a chromogenic substrate of TPA (tissue plasminogen activator). D-Val-Gly-Arg-pNA can be used to detect the amidolytic activity of TPA I and TPA II.
    D-Val-Gly-Arg-pNA
  • HY-P10014
    Bibapcitide 153507-46-1 98%
    Bibapcitide, a 26 amino acid, inhibits thrombosis.
    Bibapcitide
  • HY-P10092
    SP6 98%
    SP6 exertes an antihypertensive effect through vascular NO regulation.
    SP6
  • HY-P10135
    RES-701-1 151308-34-8 98%
    RES-701-1 is a cyclic peptide composed of 16 common L-amino acids, acting as a specific antagonist for the ETB receptor. RES-701-1 can inhibit the binding of 125I-ET-1 (125I-labeled Endothelin (ET)-1) to the ETB receptor, with an IC50 value of 10 nM.
    RES-701-1
  • HY-P10151
    PD 156252 175592-65-1 98%
    PD 156252 is a hexapeptide that is a highly potent endothelin (ET) antagonist. PD 156252 has enhanced binding affinity for rabbit ETA and rat ETB receptor subtypes with IC50 values of 1.0 and 40 nM, respectively.
    PD 156252
  • HY-P1016B
    BQ-3020 ammonium 99.18%
    BQ-3020 ammonium is a selective endothelin receptor (ETB receptor) agonist. BQ-3020 ammonium inhibits [125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 ammonium elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 ammonium makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research. .
    BQ-3020 ammonium
  • HY-P10186
    Myristoylated ARF6 (2-13), scrambled 98%
    Myristoylated ARF6 (2-13), scrambled is a peptide , and is composed of amino acids 2–13 of ARF6 (MyrARF6 2–13).
    Myristoylated ARF6 (2-13), scrambled
  • HY-P10188
    apoB (4372-4392) 255822-48-1 98%
    apoB (4372-4392) is a potent lipoprotein(a) assembly inhibitor, with an IC50 of 40 μM. apoB (4372-4392) can noncovalently bind to apolipoprotein(a) with high affinity.
    apoB (4372-4392)
  • HY-P1019A
    [Ala1,​3,​11,​15]​-​Endothelin (53-63) (TFA) 98%
    [Ala1,3,11,15]-Endothelin (53-63) (TFA) is an ETB agonist. [Ala1,3,11,15]-Endothelin (53-63) (TFA) has selectivity for ETB with IC50 values range from 0.33 nM to 0.61 nM. [Ala1,3,11,15]-Endothelin (53-63) (TFA) can be used for the research of vasoconstriction.
    [Ala1,​3,​11,​15]​-​Endothelin (53-63) (TFA)
  • HY-P10258
    KRES peptide 867376-23-6 98%
    KRES peptide is an apolipoprotein with 4 amino acid residues. KRES peptide interacts with lipids, reduces lipoprotein lipid hydroperoxides (LOOH), activates antioxidant enzymes associated with high-density lipoprotein. KRES peptide exhibits anti-inflammatory and anti-atherogenic properties. KRES peptide is orally active.
    KRES peptide
  • HY-P10268
    Neuropeptide K (human, porcine, rat) 96827-05-3 98%
    Neuropeptide K, human, porcine, rat exhibits bioactivity in gallbladder contraction, protein extravasation, hypotension and brcnchial smooth muscle spasm. Neuropeptide K, human, porcine, rat is concentrated in brain and acts as tachykinin neuromessenger.
    Neuropeptide K (human, porcine, rat)
  • HY-P10319
    RI-STAD-2 98%
    RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer.
    RI-STAD-2
  • HY-P10320
    T3 Peptide 98%
    T3 Peptide is an active fragment of tumstatin. T3 Peptide binds integrin αvβ3/αvβ5, activates the PI3K/Akt/p70S6K signaling pathway, and thus stimulates the proliferation and migration of rat cardiac fibroblasts.
    T3 Peptide
  • HY-P10325
    Kalata B7 339532-29-5 98%
    Kalata B7 is a cyclotide that can be isolated from Oldenlandia affinis DC (Rubiaceae) and possesses membrane-permeating capabilities. Kalata B7 is also a partial agonist of oxytocin and vasopressin V1a receptors.
    Kalata B7
  • HY-P10342
    Soystatin 510725-34-5 98%
    Soystatin is a peptide extracted from soy protein, whose main activity is to inhibit the absorption of cholesterol. Soystatin, as a peptide with significant cholic acid binding ability, can be used in the study of cardiovascular diseases.
    Soystatin
  • HY-P10346
    smMLCK peptide 172960-20-2 98%
    smMLCK peptide is a specific inhibitor of smooth muscle myosin light chain kinase (smMLCK). The smMLCK peptide mimics the substrate and competitively inhibits the binding of the actual substrate to the enzyme, thereby inhibiting the kinase activity. This inhibition prevents the phosphorylation of the myosin light chain, thus inhibiting muscle contraction.
    smMLCK peptide
  • HY-P10551
    Apo A-I mimetic 5A peptide 98%
    Apo A-I mimetic 5A peptide is a synthetic peptide molecule designed based on the structure and function of naturally occurring apolipoprotein A-I (Apo A-I). Apo A-I mimetic 5A peptide can promote the efflux of cholesterol from cells and help reduce the accumulation of cholesterol in cells. Apo A-I mimetic 5A peptide also shows anti-inflammatory activity and can reduce inflammatory markers in blood and tissues. Apo A-I mimetic 5A peptide can be used in the study of cardiovascular diseases.
    Apo A-I mimetic 5A peptide
  • HY-P10577
    RAG8 peptide 98%
    RAG8 peptide is an antagonist for protease-activated receptor 4 (PAR 4), which inhibits late-stage platelet activation, and reduces thrombosis without altering hemostasis or increasing bleeding risk. RAG8 peptide can be used for atherosclerosis research.
    RAG8 peptide
  • HY-P10586
    Macrophage-activating lipopeptide 2 250718-44-6 98%
    Macrophage-activating lipopeptide 2 (MALP-2) is an agonist of Toll like receptors TLR-2/TLR-6. Macrophage-activating lipopeptide-2 can enhance endothelial nitric oxide synthase (eNOS) phosphorylation and endothelial cell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 can enhance endothelial adhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL).
    Macrophage-activating lipopeptide 2
  • HY-P10601
    αs1-CN f(143–149) 916608-63-4 98%
    αs1-CN f(143–149) is an orally active casein-derived peptide sequence. αs1-CN f(143–149) exhibits angiotensin-converting enzyme (ACE) inhibitory activity (IC50=6.58 μM) and antihypertensive activity.
    αs1-CN f(143–149)
Cat. No. Product Name / Synonyms Application Reactivity